JP2015501814A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501814A5
JP2015501814A5 JP2014546016A JP2014546016A JP2015501814A5 JP 2015501814 A5 JP2015501814 A5 JP 2015501814A5 JP 2014546016 A JP2014546016 A JP 2014546016A JP 2014546016 A JP2014546016 A JP 2014546016A JP 2015501814 A5 JP2015501814 A5 JP 2015501814A5
Authority
JP
Japan
Prior art keywords
binding polypeptide
amino acid
acid sequence
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546016A
Other languages
English (en)
Japanese (ja)
Other versions
JP6483442B2 (ja
JP2015501814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/067909 external-priority patent/WO2013085972A1/en
Publication of JP2015501814A publication Critical patent/JP2015501814A/ja
Publication of JP2015501814A5 publication Critical patent/JP2015501814A5/ja
Application granted granted Critical
Publication of JP6483442B2 publication Critical patent/JP6483442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546016A 2011-12-05 2012-12-05 Pdgf受容体ベータ結合ポリペプチド Active JP6483442B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566778P 2011-12-05 2011-12-05
US61/566,778 2011-12-05
US201261610905P 2012-03-14 2012-03-14
US61/610,905 2012-03-14
PCT/US2012/067909 WO2013085972A1 (en) 2011-12-05 2012-12-05 Pdgf receptor beta binding polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018216510A Division JP6843816B2 (ja) 2011-12-05 2018-11-19 Pdgf受容体ベータ結合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2015501814A JP2015501814A (ja) 2015-01-19
JP2015501814A5 true JP2015501814A5 (2) 2016-01-14
JP6483442B2 JP6483442B2 (ja) 2019-03-13

Family

ID=48574820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546016A Active JP6483442B2 (ja) 2011-12-05 2012-12-05 Pdgf受容体ベータ結合ポリペプチド
JP2018216510A Expired - Fee Related JP6843816B2 (ja) 2011-12-05 2018-11-19 Pdgf受容体ベータ結合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018216510A Expired - Fee Related JP6843816B2 (ja) 2011-12-05 2018-11-19 Pdgf受容体ベータ結合ポリペプチド

Country Status (9)

Country Link
US (4) US9416179B2 (2)
EP (2) EP2788379B1 (2)
JP (2) JP6483442B2 (2)
CN (2) CN104105708B (2)
AU (1) AU2012347972B2 (2)
CA (1) CA2857721C (2)
ES (1) ES2784131T3 (2)
TW (2) TWI591074B (2)
WO (1) WO2013085972A1 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
ES2873375T3 (es) 2011-03-15 2021-11-03 X Body Inc Métodos de cribado de anticuerpos
CN104105708B (zh) * 2011-12-05 2018-04-03 X博迪生物科学公司 PDGF受体β结合多肽
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PL2827863T3 (pl) 2012-03-20 2019-07-31 Eagle Pharmaceuticals, Inc. Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
CN105026433B (zh) * 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
ES2800674T3 (es) * 2014-03-21 2021-01-04 X Body Inc Polipéptidos biespecíficos de unión a antígeno
CN118772278A (zh) 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
WO2020071881A1 (ko) * 2018-10-05 2020-04-09 서울대학교산학협력단 Pdgf 수용체에 대한 항체 및 이의 용도
JP2020146302A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146310A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146303A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146307A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146306A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146301A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146315A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146308A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146311A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146304A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146316A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146314A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146300A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146299A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146317A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146312A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146298A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146297A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146305A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146309A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146318A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
CA3285695A1 (en) 2019-06-26 2026-03-02 Ap Biosciences, Inc. Antibodies for t-cell activation
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
US20230340112A1 (en) * 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
CN114369163B (zh) * 2022-02-18 2024-02-23 中国科学技术大学 与人血小板衍生生长因子受体β结合的羊驼源纳米抗体
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
CN121378405A (zh) * 2025-11-28 2026-01-23 首都医科大学附属北京口腔医院 一种pdgfd衍生肽及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO2001007657A1 (en) 1999-07-27 2001-02-01 Phylos, Inc. Peptide acceptor ligation methods
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
EP0619738B1 (en) * 1991-12-02 2003-07-09 Millennium Pharmaceuticals, Inc. Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
EP1105360B1 (en) 1998-08-17 2009-07-29 Bristol-Myers Squibb Company Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
JP2002522091A (ja) 1998-08-17 2002-07-23 フィロス インク. 3’非翻訳領域を欠損する核酸を生成して細胞rna蛋白質融合体形成を最適化する方法
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
AU779491B2 (en) 1999-06-01 2005-01-27 Bristol-Myers Squibb Company Methods for producing 5'-nucleic acid-protein conjugates
EP1194594A4 (en) 1999-07-12 2005-06-01 Compound Therapeutics Inc MARKING OF PROTEINS AT C-TERMINUS
AU779653B2 (en) 1999-08-27 2005-02-03 Bristol-Myers Squibb Company Methods for encoding and sorting in vitro translated proteins
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
WO2001053539A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
CA2443862A1 (en) 2001-04-17 2002-10-24 Peizhi Luo Structure-based construction of human antibody library
US6951725B2 (en) 2001-06-21 2005-10-04 Compound Therapeutics, Inc. In vitro protein interaction detection systems
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7125669B2 (en) 2001-11-27 2006-10-24 Compound Therapeutics, Inc. Solid-phase immobilization of proteins and peptides
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
GB0226729D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US20080206585A1 (en) * 2007-02-22 2008-08-28 Kennametal Inc. Composite materials comprising a hard ceramic phase and a Cu-Ni-Mn infiltration alloy
MX2009011226A (es) 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
EP2157937B1 (en) 2007-06-04 2017-03-22 Sequent Medical, Inc. Devices for treatment of vascular defects
WO2009120922A2 (en) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
EP3629022A1 (en) 2008-07-25 2020-04-01 Richard W. Wagner Protein screening methods
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
ES2873375T3 (es) * 2011-03-15 2021-11-03 X Body Inc Métodos de cribado de anticuerpos
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
CN104105708B (zh) * 2011-12-05 2018-04-03 X博迪生物科学公司 PDGF受体β结合多肽

Similar Documents

Publication Publication Date Title
JP2015501814A5 (2)
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
JP2020023523A5 (2)
ES2662519T3 (es) Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
JP2015501149A5 (2)
HRP20140244T1 (hr) Sastavi i metode za inhibiranje pdgfrbeta i vegf-a
JP2014503189A5 (2)
RU2018102798A (ru) Антитела к фактору xi и способы их применения
AR086360A1 (es) Polipeptidos anticuerpos que antagonizan cd40
JP2009545325A5 (2)
JP2014158480A5 (2)
JP2016537966A5 (2)
HRP20201528T1 (hr) Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama
JP2019506841A5 (2)
JP2018521691A5 (2)
KR20160113272A (ko) Tim-3에 대한 항체 분자 및 그의 용도
JP2016539096A5 (2)
JP2012524524A5 (2)
JP2014530215A5 (2)
JP2009535021A5 (2)
JP2015143226A5 (2)
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2013527761A5 (2)
JP2016519124A5 (2)